Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an ...

As for FibroGen’s roxadustat, the drug has fallen victim to a string of setbacks in the U.S. that culminated in late February ...

As industries around the globe wrestle with where and how often artificial intelligence (AI) should be implemented in their ...

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing ...

Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. | Roche isn’t content with ...

AstraZeneca has tapped an ice hockey player who knows a thing or two about checking for the latest spin on its NHL-partnered ...

The initiative comes nearly two years after the EC launched an investigation surrounding Vifor’s alleged efforts to disparage ...

Immunology is AbbVie’s world, everyone else just lives in it. | Immunology is AbbVie’s world, everyone else just lives in it. That is the takeaway from ZoomRx’s analysis of the perceptions of ...

Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition ...

During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. | During a busy ...

After Adstiladrin's FDA approval in late 2022, Ferring Pharmaceuticals finally established unfettered supply of the bladder ...

History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up ...